Uveitis Affecting the Posterior Segment Clinical Trial
— IluvienOfficial title:
Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis
| NCT number | NCT01781936 |
| Other study ID # | Pro00033019 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 1 |
| First received | |
| Last updated | |
| Start date | June 2012 |
| Est. completion date | June 13, 2018 |
| Verified date | December 2019 |
| Source | Duke University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine the tolerability, safety, and benefits of an investigational drug,Fluocinolone Acetonide Intravitreal Insert (FA-i), in people who have posterior uveitis. The study drug, Fluocinolone Acetonide, is currently used in a surgical implant, Retisert, which is approved by the U.S. Food and Drug Administration (FDA) to treat non-infectious posterior uveitis . The study drug is able to be inserted in an ophthalmology (eye) clinic; whereas Retisert must be surgically implanted in the Operating Room. Initially, this was a 2-dose randomized pilot study. However, the study was modified to include only the 0.2 ug/day implant.
| Status | Completed |
| Enrollment | 17 |
| Est. completion date | June 13, 2018 |
| Est. primary completion date | June 13, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: 1. At least 18 years old at time of consent. 2. One or both eyes with a minimum of 1 year history of recurrent non-infectious uveitis affecting the posterior segment requiring either a) systemic corticosteroid or other equivalent non-steroidal immunosuppressive agent given for at least 3 months prior to enrollment OR at least 2 sub-Tenon's injections of corticosteroid for management of uveitis during 6 months prior to enrollment OR at least 2 separate recurrences of uveitis within 6 months prior to enrollment requiring systemic, intravitreal or sub-Tenon's injection of corticosteroid OR recurrence of uveitis after having received an intravitreal steroid implant (Ozurdex or Retisert) OR unable to tolerate the side effects of therapy with systemic corticosteroid or other equivalent non-steroidal immunosuppressive agent OR recurrence of uveitis after having received an FAi (Fluocinolone Acetonide intravitreal insert). 3. Negative serum pregnancy test at baseline for women of childbearing potential. 4. An informed consent document signed and dated by the subject or a legally acceptable representative. 5. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: Subjects presenting with any of the following will not be included in the study: 1. History of glaucoma in the study eye 2. Allergy to corticosteroids of any component of delivery system 3. History of iridocyclitis only and no vitreous cells or vitreous haze in the study eye 4. Uveitis with infectious etiology in the study eye 5. Vitreous hemorrhage in the study eye 6. Toxoplasmosis scar in study eye 7. Media opacity precluding evaluation of retina and vitreous in the study eye 8. Peripheral retinal detachment in area of insertion in the study eye 9. Elevated Intraocular pressure (IOP) >21 on no more than 1 anti-ocular hypertensive medication in the study eye 10. History of elevated IOP (Intraocular Pressure)(above 22 mmHg) in the study eye while on corticosteroids unless the subject has previously undergone filtration surgery (tube shunt or trabeculectomy) following the episode of steroid-associated ocular hypertension. In the latter case, the subject will be eligible for enrollment, provided that the intraocular pressure is controlled at < 21 mmHg on no more than one anti-ocular hypertensive medication. 11. Ocular surgery in the study eye within 3 months prior to enrollment requiring chronic systemic therapy 12. Systemic immunosuppressive therapy to manage non-ocular disease 13. Patients who have tested positive for human immune deficiency virus 14. Pregnant females 15. Patients for whom any of the protocol procedures may pose a special risk not outweighed by the potential benefits of participating in the study 16. Patients who are unlikely to comply with the study protocol 17. Any severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, could make the patient inappropriate for entry into this study. 18. Treatment with an investigational drug or device in the study eye within 30 days preceding the device placement. 19. Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to the first dose of study medication and throughout the study. - |
| Country | Name | City | State |
|---|---|---|---|
| United States | Duke Eye Center | Durham | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Glenn Jaffe |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in status of uveitis in study eye. | Anterior chamber cells will be measured using a Haag-Streit Slit Lamp at high magnification (1.6 X) x 1mm beam. Assessment will be made using the Standardization of Uveitis Nomenclature (SUN) scale. Ophthalmoscopy will be performed to assess vitreous haze, which will be graded according to the scale provided with photographs reproduced from Nussenblatt et al, (Ophthalmology 92:467-471, 1985). |
Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in IOP (intraocular pressure) in study eye. | Goldmann tonometry will be used to measure IOP. | Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in lens status in study eye. | Lens changes will be assessed with a Haag-Streit Slit Lamp. | Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in endophthalmitis in study eye. | The study eye will be evaluated for endophthalmitis by undergoing inspection with a Haag Streit Slit Lamp and an indirect ophthalmoscope. | Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in vitreous status in study eye. | A Haag-Streit Slit Lamp and an indirect ophthalmoscope will be used to assess for any hemorrhaging in the study eye. | Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in retinal status in study eye. | The retina will be evaluated using a Haag Streit Slit Lamp and an indirect ophthalmoscope. | Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in macular thickness in study eye. | Spectralis SD-OCT will be used to assess macular thickness. | Assessed at Screening, Day 14, 28, Months 2, 3, 6, 9, 12, 15, 18, 21, and 24. | |
| Secondary | Change in Best Corrected Visual Acuity in the study eye. | The visual acuity is measured according to the standard procedure developed for the Early Treatment Diabetic Retinopathy Study (ETDRS) and adapted for the Age-Related Eye Disease Study (AREDS). | Assessed at Screening, Day 0, Day 1, Day 14, Day 28, Months 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24. |